These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2941573)

  • 21. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ; Reneman RS
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker.
    Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G
    Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173
    [No Abstract]   [Full Text] [Related]  

  • 23. [Plasma endothelin concentration during cold provocation in primary Raynaud's syndrome].
    von Bierbrauer A; Ehlenz K; Herzog P; Cassel W; von Wichert P
    Dtsch Med Wochenschr; 1995 Jun; 120(25-26):902-6. PubMed ID: 7600925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
    Longstaff J; Gush R; Williams EH; Jayson MI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
    Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A
    Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
    Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
    Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis and treatment of Raynaud's phenomenon.
    Coffman JD
    Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():45-51. PubMed ID: 2285650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of ketanserin in hypertension and vasospastic disease.
    Wenting GJ; Brouwer RM; vd Meiracker AJ; Man in't Veld AJ; Schalekamp MA
    Acta Cardiol; 1987; 42(5):339-54. PubMed ID: 2827406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
    Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
    Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
    [No Abstract]   [Full Text] [Related]  

  • 33. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.
    Bounameaux HM; Hellemans H; Verhaege R
    Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
    Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
    J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanisms of Raynaud's disease.
    Cooke JP; Marshall JM
    Vasc Med; 2005 Nov; 10(4):293-307. PubMed ID: 16444858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aerosol spray can induced cold injury in a patient with Raynaud's phenomenon.
    Olive KE
    J Rheumatol; 1990 Apr; 17(4):556-7. PubMed ID: 2348437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
    Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
    J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous nicardipine in Raynaud's phenomenon: a controlled trial.
    van Heereveld H; Wollersheim H; Gough K; Thien T
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):68-74. PubMed ID: 2450259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Validity of plethysmography and the digital temperature recovery test in the diagnosis of primary and occupational Raynaud's phenomenon].
    Laroche GP; Thériault G
    Clin Invest Med; 1987 Mar; 10(2):96-102. PubMed ID: 3581549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.